(EMAILWIRE.COM, January 09, 2018 ) The Global Nuclear Medicine Radiopharmaceuticals Market is estimated at USD 4500 million in 2015 and is expected to reach USD 8440 million by 2020, growing at a CAGR of 13.4%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.

Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/request-sample

Increasing incidence of cancer and cardiac ailments, immense technological advancements, increasing demand SPECT and PET applications and also the growing public awareness for healthcare are fuelling the market growth for Radiopharmaceuticals. Further, Integration of X ray tomography (CT) into SPECT has recently emerged as a excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory framework which pose as a hurdle to translational research and clinical investigations and reimbursement issues are blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also restraining the global nuclear medicine Radioisotopes market.

Buy now @ http://www.marketdataforecast.com/cart/buy-now/global-nuclear-medicine-radiopharmaceuticals-market-130/

Global Nuclear Medicine Radiopharmaceuticals Market Segmentation

1. By Type
a. Diagnostic Radioisotopes
b. SPECT
c. PET

2. Therapeutic Radioisotopes
a. Beta Emitters

3. By Application
a. Cardiology
b. Lymphoma
c. Thyroid
d. Neurology
e. Oncology
f. Others

Based on market share estimation 90 % of the radiopharmaceuticals market is dominated by diagnostic radioisotopes while therapeutic radioisotopes contribute 10% of the market. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.

North America is the dominant market for diagnostic radioisotopes. Within North America, US is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m. India and China hold a potential market for radioisotope due to rising healthcare and increasing demand for different radioisotopes in various treatments and applications.

Some of the key players influencing the global nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.

About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com

Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results